A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer
Xiao X Wei, Adam P Siegel, Rahul Aggarwal, Amy M Lin, Terence W Friedlander, Lawrence Fong, Won Kim, Mirela Louttit, Emily Chang, Li Zhang, Charles J Ryan, Xiao X Wei, Adam P Siegel, Rahul Aggarwal, Amy M Lin, Terence W Friedlander, Lawrence Fong, Won Kim, Mirela Louttit, Emily Chang, Li Zhang, Charles J Ryan
Abstract
Lessons learned: In abiraterone- and/or enzalutamide-refractory metastatic castration-resistant prostate cancer (mCRPC) patients, selinexor led to prostate-specific antigen and/or radiographic responses in a subset of patients, indicating clinical activity in this indication.Despite twice-a-week dosing and maximal symptomatic management, selinexor was associated with significant anorexia, nausea, and fatigue in mCRPC patients refractory to second-generation anti-androgen therapies, limiting further clinical development in this patient population.This study highlights the challenge of primary endpoint selection for phase II studies in the post-abiraterone and/or post-enzalutamide mCRPC space.
Background: Selinexor is a first-in-class selective inhibitor of nuclear export compound that specifically inhibits the nuclear export protein Exportin-1 (XPO-1), leading to nuclear accumulation of tumor suppressor proteins.
Methods: This phase II study evaluated the efficacy and tolerability of selinexor in patients with metastatic castration-resistant prostate cancer (mCRPC) refractory to abiraterone and/or enzalutamide.
Results: Fourteen patients were enrolled. Selinexor was initially administered at 65 mg/m2 twice a week (days 1 and 3) and was subsequently reduced to 60 mg flat dose twice a week (days 1 and 3), 3 weeks on, 1 week off, to improve tolerability. The median treatment duration was 13 weeks. At a median follow-up of 4 months, two patients (14%) had ≥50% prostate-specific antigen (PSA) decline, and seven patients (50%) had any PSA decline. Of eight patients with measurable disease at baseline, two (25%) had a partial response and four (50%) had stable disease as their best radiographic response. Five patients (36%) experienced serious adverse events (SAEs; all unrelated to selinexor), and five patients (36%) experienced treatment-related grade 3-4 AEs. The most common drug-related adverse events (AEs) of any severity were anorexia, nausea, weight loss, fatigue, and thrombocytopenia. Three patients (21%) came off study for unacceptable tolerability.
Conclusion: Selinexor demonstrated clinical activity and poor tolerability in mCRPC patients refractory to second-line anti-androgenic agents.
Trial registration: ClinicalTrials.gov NCT02215161.
©AlphaMed Press; the data published online to support this summary is the property of the authors.
Figures
References
- Nigg EA. Nucleocytoplasmic transport: Signals, mechanisms and regulation. Nature 1997;386:779–787.
- Fukuda M, Asano S, Nakamura T et al. CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature 1997;390:308–311.
- Kau TR, Way JC, Silver PA. Nuclear transport and cancer: From mechanism to intervention. Nat Rev Cancer 2004;4:106–117.
- Gravina GL, Mancini A, Sanita P et al. KPT‐330, a potent and selective exportin‐1 (XPO‐1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models. BMC Cancer 2015;15:941.
- Gravina GL, Tortoreto M, Mancini A et al. XPO1/CRM1‐selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa). J Hematol Oncol 2014;7:46.
- Maity S, Wu G, Lu J et al. Preclinical efficacy of the novel, oral selective inhibitor of nuclear export (SINE) selinexor (KPT‐330) on castration resistant prostate cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; April 5–9, 2014; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(suppl 19):3808a.
- Mendonca J, Sharma A, Kim HS et al. Selective inhibitors of nuclear export (SINE) as novel therapeutics for prostate cancer. Oncotarget 2014;5:6102–6112.
- Ryan CJ, Smith MR, de Bono JS et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138–148.
- de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995–2005.
- Beer TM, Armstrong AJ, Rathkopf DE et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371:424–433.
- Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187–1197.
- Antonarakis ES, Armstrong AJ, Dehm SM et al. Androgen receptor variant‐driven prostate cancer: Clinical implications and therapeutic targeting. Prostate Cancer Prostatic Dis 2016;19:231–241.
- Scher HI, Lu D, Schreiber NA et al. Association of AR‐V7 on circulating tumor cells as a treatment‐specific biomarker with outcomes and survival in castration‐resistant prostate cancer. JAMA Oncol 2016;2:1441–1449.
- Antonarakis ES, Lu C, Luber B et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration‐resistant prostate cancer. JAMA Oncol 2015;1:582–591.
- Abdul Razak AR, Mau‐Soerensen M, Gabrail NY et al. First‐in‐class, first‐in‐human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors. J Clin Onocl 2016;34:4142–4150.
- Alexander TB, Lacayo NJ, Choi JK et al. Phase I study of selinexor, a selective inhibitor of nuclear export, in combination with fludarabine and cytarabine, in pediatric relapsed or refractory acute leukemia. J Clin Oncol 2016;34:4094–4101.
- Kuruvilla J, Savona M, Baz R et al. Selective inhibition of nuclear export with selinexor in patients with non‐Hodgkin lymphoma. Blood 2017;129:3175–3183.
- Gounder MM, Zer A, Tap WD et al. Phase IB study of selinexor, a first‐in‐class inhibitor of nuclear export, in patients with advanced refractory bone or soft tissue sarcoma. J Clin Oncol 2016;34:3166–3174.
- Vergote I, Lund B, Havsteen H et al. Results of a phase 2 trial of selinexor, an oral selective inhibitor of nuclear export (SINE) in 114 patients with gynaecological cancers. Ann Oncol 2016;27:296–312.
- Etchin J, Berezovskaya A, Conway AS et al. KPT‐8602, a second‐generation inhibitor of XPO1‐mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia‐initiating cells. Leukemia 2017;31:143–150.
- Vercruysse T, De Bie J, Neggers JE et al. The second‐generation exportin‐1 inhibitor KPT‐8602 demonstrates potent activity against acute lymphoblastic leukemia. Clin Cancer Res 2017;23:2528–2541.
- Cornell RF, Rossi AC, Baz R et al. A phase 1/2 study of the second generation selective inhibitor of nuclear export (SINE) compound, KPT‐8602, in patients with relapsed refractory multiple myeloma. Blood 2016;128:4509.
Source: PubMed